Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 3/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18748463 | 1.00 | ATM (0.53) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL6835510 | 0.88 | ATM (0.54) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL7408378 | 0.88 | ATM (0.54) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL13109024 | 0.88 | ATM (0.54) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL7427102 | 0.87 | SYK (0.49) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL6874791 | 0.86 | ATM (0.53) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL21609299 | 0.86 | ATM (0.53) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL7428131 | 0.85 | MEN1 (0.53) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL12295162 | 0.85 | CTSS (0.50) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL12166523 | 0.84 | ATM (0.51) | ATMSYKCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20120329724-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED | 2012-12-27 | — | — | US | disclosed |
| US-20120329724-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED | 2012-12-27 | — | — | US | disclosed |
| WO-2011104649-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED (GB) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207654-A1 | PEPTIDE ANALOGUES | PFIZER INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207654-A1 | PEPTIDE ANALOGUES | PFIZER INC. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | ATM 3650/4885SYK 2872/4885CTSS 3011/4885 |
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | ATM 3650/4885SYK 2872/4885CTSS 3011/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | ATM 3650/4885SYK 2872/4885CTSS 3011/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | ATM 3650/4885SYK 2872/4885CTSS 3011/4885 |
| US-20120329724-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | ATM 4874/4885SYK 3794/4885CTSS 1734/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | ATM 3650/4885SYK 2872/4885CTSS 3011/4885 |
| US-20110207654-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | ATM 4874/4885SYK 3794/4885CTSS 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.